TARS · NASDAQ · Biotechnology

Tarsus Pharmaceuticals (TARS)

Commercializes XDEMVY for Demodex blepharitis and develops additional eye-care and infectious-disease therapies.

$76.15
vs last close−0.93 (−1.20%)